Concepedia

Anna Kryzhanivska

AK

Statistics

Publications

16

Citations

7.1K

H-Index

15

Active since

2018

Affiliations

Ivano-Frankivsk National Medical University(Current)

Merck & Co., Inc., Rahway, NJ, USA (United States)

Dnipro State Medical University

Fox Chase Cancer Center

Fondazione IRCCS Istituto Nazionale dei Tumori

Anna Kryzhanivska is an author at Ivano-Frankivsk National Medical University specializing in oncology, medicine, and cancer pharmacology.

ORCID

Publications per year

2018–2025

16

Publications

16

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Brian I. Rini, Elizabeth R. Plimack, V.P. Stus et al. · New England Journal of Medicine · 2019 · 3.4K citations · Full text

, , +9

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Luis Paz‐Ares, Mikhail Dvorkin, Yuanbin Chen et al. · The Lancet · 2019 · 2.2K citations

, , +14

Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

Jonathan W. Goldman, Mikhail Dvorkin, Yuanbin Chen et al. · The Lancet Oncology · 2020 · 687 citations · Full text

, , +14

Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

B. Sangro, Stephen L. Chan, Robin Kate Kelley et al. · Annals of Oncology · 2024 · 312 citations · Full text

, , +16

Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from 42-month follow-up of KEYNOTE-426.

Brian I. Rini, Elizabeth R. Plimack, V.P. Stus et al. · Journal of Clinical Oncology · 2021 · 109 citations

, , +15

1–5 of 16